Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2021-12-13 Regulatory Filings
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-12-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a pre-IND meeting with the FDA regarding the development of a drug candidate (PD-001) for COVID-19 treatment. It discusses regulatory feedback, clinical development plans, and future intentions for clinical trials. There are no financial statements, earnings data, or detailed financial analysis. The content is focused on regulatory and development updates rather than financial reporting. It is not a report itself but an announcement of regulatory progress and plans. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-11-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-11-29 English
Interim MD&A - English.pdf
Regulatory Filings
2021-11-29 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document contains only references to omitted pictures and has a very short length (327 characters). There is no textual content indicating any report, announcement, or detailed information. Given the lack of substantive content, this document does not fit any specific report or announcement category and defaults to the fallback category for miscellaneous filings.
2021-11-18 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing PharmaDrug's advancement in its psychedelics program, specifically focusing on DMT analogue molecules for treating eye diseases such as glaucoma. It discusses research agreements, preclinical studies, and future plans for drug development. There are no financial statements, regulatory filings, or detailed financial performance data. The document is informational and promotional in nature, typical of a corporate press release about research and development progress. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a presentation or transcript, nor does it announce voting results or capital changes. Given the content and style, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-11-05 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.